Author archive for Syntrix

AUBURN, WASHINGTON — In collaboration with Syntrix Pharmaceuticals, researchers at the University of Texas MD Anderson Cancer Center revealed that…

AUBURN, WASHINGTON — Syntrix Pharmaceuticals today announced the initiation of a Phase 2 study evaluating the efficacy and safety of…

AUBURN, WASHINGTON — Syntrix Pharmaceuticals announced this week that it has been awarded a three-year grant worth $3.4 million from…

Desmetramadol featured today in new article by Research Outreach entitled, “Moving beyond dangerous opioids for pain: Syntrix creates new drug…

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean…

Syntrix today announced that the World Health Organization’s International Nonproprietary Name (INN) group have accepted the proposed generic name “Desmetramadol”…

Syntrix today announced their participation in the NCI Formulary, a public-private partnership between the National Cancer Institute (NCI), part of…

Large patient populations treated with dangerous Schedule II opioids are expected to benefit from Omnitram, a safer alternative without metabolic…

Congratulations to Syntrix scientists on their latest issued patents at the United States Patent and Trademark Office.  ‘701 Abstract: Disclosed…

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean…